New-onset mental disorders increase among patients with metabolic diseases after the COVID-19 pandemic

作者：Jeong Min Cho, Juhwan Oh, Jung Hun Koh, Minsang Kim, S. Kim, Semin Cho, Soojin Lee, Yaerim Kim, Yong Chul Kim, Seung Seok Han, Hajeong Lee, Kwon Wook Joo, Yon Su Kim, Dong Ki Kim, Sehoon Park · 发表于：Scientific Reports · 年份：2025 · DOI：10.1038/s41598-025-99280-6 · 被引用次数：2 · 研究领域：COVID-19 and Mental Health、Long-Term Effects of COVID-19、Bipolar Disorder and Treatment

There is limited information on new-onset mental disorders in adults with metabolic diseases following the COVID-19 pandemic. Here, we aimed to examine the changes in mental health following the COVID-19 pandemic and identify factors associated with the development of new-onset mental disorders. Among 90,580 UK Biobank participants diagnosed with COVID-19 between Jan 31, 2020 and Oct 31, 2022, those who completed both baseline and follow-up mental health questionnaires in 2016-2017 and 2022-2023 were included in the analysis. New-onset depression, anxiety, and alcohol use disorder following the COVID-19 pandemic, as well as changes in mental health scores, were assessed. Furthermore, their association with sociodemographic, clinical, and self-perceived emotional state-related exposures was examined. Prevalent metabolic diseases were significantly associated with a higher risk of new-onset depression (hypertension: odds ratio [OR], 1.22; 95% CI 1.01-1.47; diabetes: OR 1.8; 95% CI 1.25-2.6; obesity: OR 1.66; 95% CI 1.43-1.95) and anxiety (hypertension: OR 1.32; 95% CI 1.06-1.63; diabetes: OR 1.66; 95% CI 1.06-2.62; obesity: OR 1.2; 95% CI 0.99-1.44) following COVID-19 pandemic. There was a significant increase of Patient Health Questionnaire-9 (PHQ-9; beta, 0.32; 95% CI 0.29-0.35) and Generalized Anxiety Disorder-7 (GAD-7; beta, 0.10; 95% CI 0.06-0.13) scores throughout the COVID-19 pandemic, while Alcohol Use Disorder Identification Test (AUDIT) score decreased over time (beta...